# MCAS interventions evidence

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Guide
Updated: 2026-10-16
Canonical: https://heretic.bio/articles/mcas-interventions-evidence.html

> Pharmacologic MCAS treatment (H1/H2 antihistamines, cromolyn, leukotriene antagonists, omalizumab for chronic urticaria, and a few emerging targeted biologics) has the strongest evidence base. Dietary and nutraceutical interventions (DAO enzyme, vitamin C, quercetin, luteolin, low-histamine diet) have moderate evidence in narrow indications but lack the RCT base for MCAS specifically. The supplements Andra promotes are mostly safe at typical doses but should not replace mainstream MCAS treatment.

## Tier 1 — Mainstream MCAS treatment

Intervention | Evidence rating | Trial | Outcome  
---|---|---|---  
H1 antihistamines (cetirizine, loratadine, hydroxyzine, ketotifen) | 4 | Systematic review (PMID [26095756](https://pubmed.ncbi.nlm.nih.gov/26095756/)); Weiler 413-patient series (PMID [28262205](https://pubmed.ncbi.nlm.nih.gov/28262205/)) | ~70% of MCAS patients report at least partial symptom improvement on H1 + H2 combination.[63][75]  
H2 antihistamines (famotidine, ranitidine) | 4 | Same as above | Adjunct to H1; particularly useful for GI symptoms.[63][75] Famotidine activates the vagal inflammatory reflex (PMID [35578169](https://pubmed.ncbi.nlm.nih.gov/35578169/)).[74]  
Cromolyn sodium (oral) | 3 | Open-label pediatric and adult series; case series in MCAS (PMID [30964355](https://pubmed.ncbi.nlm.nih.gov/30964355/), 41728426) | Effective for GI-dominant MCAS; pediatric high-dose oral cromolyn series in ME/CFS showed benefit in subset.[26][65]  
Leukotriene receptor antagonists (montelukast) | 3 | Open-label; included in most MCAS step-therapy | Useful for respiratory and skin flares.[30]  
Omalizumab (anti-IgE) | 4 | Large RCTs in chronic urticaria (separate from MCAS, but mechanistically overlapping) | FDA-approved for chronic spontaneous urticaria; off-label for MCAS with elevated IgE.[30]  
Aspirin (low-dose) | 3 | Open-label, Weiler series | Useful in patients whose main mediator is PGD2 (cyclooxygenase-blockable); can also cause non-allergic reactions.[75]  
  
## Tier 2 — Nutraceuticals and supplements with positive but limited evidence

Intervention | Evidence rating | Best evidence | Evidence note  
---|---|---|---  
**Oral DAO enzyme** (porcine kidney extract, 4.5 mg) | 3 | RCT in episodic migraine (PMID [29475774](https://pubmed.ncbi.nlm.nih.gov/29475774/)); chronic spontaneous urticaria (PMID [29698966](https://pubmed.ncbi.nlm.nih.gov/29698966/)); fibromyalgia (PMID [37892588](https://pubmed.ncbi.nlm.nih.gov/37892588/)) | Trials typically dosed oral DAO ~15–20 min; useful when _AOC1_ polymorphisms or low serum DAO are documented.[84][83][82]  
**Vitamin C** | 3 | Hagström 1983 depletion study (PMID [8951736](https://pubmed.ncbi.nlm.nih.gov/8951736/)); Johnston 1992 (PMID [1578094](https://pubmed.ncbi.nlm.nih.gov/1578094/)); review of bronchoconstriction (PMID [25788952](https://pubmed.ncbi.nlm.nih.gov/25788952/)) | Drops whole-blood histamine in depleted subjects; helps exercise-induced bronchoconstriction. Less reliable if baseline is normal.[132][135][46]  
**Quercetin** | 3 | Mechanistic in vitro; in vivo rat PCA inhibition; small human niacin-flush study (PMID [18831918](https://pubmed.ncbi.nlm.nih.gov/18831918/)); comprehensive reviews (PMID [40362785](https://pubmed.ncbi.nlm.nih.gov/40362785/), 41305557) | Often combined with bromelain or vitamin C for absorption; modest direct MCAS evidence but reasonable safety profile.[89][86][85]  
**Luteolin** | 2 | Open-label pediatric autism pilot (PMID [23688534](https://pubmed.ncbi.nlm.nih.gov/23688534/)); mechanistic | Limited MCAS RCT data.[88]  
**Nettle (Urtica dioica)** | 2 | In vitro H1 receptor antagonism, mast-cell tryptase inhibition (PMID [19140159](https://pubmed.ncbi.nlm.nih.gov/19140159/)); mechanistic only | No MCAS clinical trial.[31]  
**Low-histamine diet** | 3 | Positive in CSU (PMID [34826140](https://pubmed.ncbi.nlm.nih.gov/34826140/)), atopic dermatitis subgroup (PMID [40431369](https://pubmed.ncbi.nlm.nih.gov/40431369/)), pediatric CSU (PMID [40880715](https://pubmed.ncbi.nlm.nih.gov/40880715/)), and natural food chemicals review (PMID [39236849](https://pubmed.ncbi.nlm.nih.gov/39236849/)) | 4–6 week elimination then structured reintroduction. But PMID [37648152](https://pubmed.ncbi.nlm.nih.gov/37648152/) (DBPC histamine challenge) shows most suspected HIT patients do not react to histamine under blinded conditions — suggests over-diagnosis.[18][119][120][118]  
  
## Tier 3 — Speculative / low-evidence

Intervention | Evidence rating | Best evidence | Evidence note  
---|---|---|---  
**Vitamin E** | 2 | Mechanistic; some evidence for combined antioxidant effect on histamine signaling | Often combined with vitamin C; no MCAS-specific RCT.  
**Beef kidney as DAO source** | 1 | In vitro DAO assay (PMID [31655856](https://pubmed.ncbi.nlm.nih.gov/31655856/)) measures activity in food matrices; no quantification of cooked beef kidney DAO activity | Beef kidney is nutrient-dense (selenium, B12, copper, B6) but the "active DAO survives digestion" claim is unproven.[59]  
**Sleep / circadian work** | 3 | Circadian variation in serum tryptase (PMID [15813817](https://pubmed.ncbi.nlm.nih.gov/15813817/)); mast-cell-sleep review (PMID [41915304](https://pubmed.ncbi.nlm.nih.gov/41915304/)) | Mechanistic + animal data; very limited human MCAS sleep trials.[117][116]  
**Stress reduction / CRH reduction** | 3 | CRH → mast cell → intestinal permeability (PMID [24153250](https://pubmed.ncbi.nlm.nih.gov/24153250/)) | Real mechanism; no MCAS-specific clinical trial but plausibly useful.[110]  
**Limbic retraining (DNRS / Annie Hopper)** | 1 | None in MCAS specifically | No primary MCAS trial of the program. Used widely in mold/CIRS community.  
**Organotherapy** | 1 | Historical (PMID [40396860](https://pubmed.ncbi.nlm.nih.gov/40396860/)) | No modern trial.  
**Cell salts (biochemic)** | 1 | Public-complementary-medicine factor analysis (PMID [10859600](https://pubmed.ncbi.nlm.nih.gov/10859600/)) | No peer-reviewed evidence for MCAS or any related indication.  
  
## Cross-cutting intervention notes

  * **H1 + H2 combination** is the bedrock of mainstream MCAS therapy. Weiler reported that most MCAS patients achieve meaningful control with H1 + H2 + mast-cell stabilizers (cromolyn or ketotifen), with biologics reserved for refractory cases.[75]
  * **Tryptase measurement** is the diagnostic test; symptom improvement is the response test. A 20% rise over baseline during a flare is the consensus-1 biochemical criterion.[5]
  * **Dietary intervention of HIT subgroup** — works; of MCAS subgroup — less clear; of mastocytosis — sometimes contraindicated (e.g., trigger avoidance may be impossible).
  * **DAO supplementation is the highest-evidence nutraceutical** in the Andra protocol. Three RCTs in three distinct indications.[82][83][84]
  * **Vitamin C** is the second-most evidence-supported; effect size is modest and depends on baseline.[132][134][135]
  * **Quercetin** is third; mostly mechanistic and indirect evidence.[86][89]
  * **Nettle and luteolin** are reasonable adjuncts but lack MCAS RCTs.



## Notes

  * Andra's protocols generally emphasize stacking supplements early; mainstream MCAS literature emphasizes H1/H2 first, then cromolyn/leukotriene, then biologics. The two converge on antihistamines as foundation; diverge on how quickly to escalate to nutraceuticals.
  * The "beef kidney as DAO source" claim deserves explicit testing: cooking temperatures typically exceed DAO thermal stability, and the DAO that survives digestion is reduced by gut pH and pancreatic proteases. A clinical trial would answer this; one has not been done.
  * The cleanest single signal in the nutraceutical evidence: **DAO enzyme supplementation for episodic migraine** (PMID [29475774](https://pubmed.ncbi.nlm.nih.gov/29475774/), 2013 RCT, positive).[84]

## Sources

1. PubMed 26095756 (PubMed 26095756)
2. PubMed 28262205 (PubMed 28262205)
3. PubMed 35578169 (PubMed 35578169)
4. PubMed 30964355 (PubMed 30964355)
5. PubMed 29475774 (PubMed 29475774)
6. PubMed 29698966 (PubMed 29698966)
7. PubMed 37892588 (PubMed 37892588)
8. PubMed 8951736 (PubMed 8951736)
9. PubMed 1578094 (PubMed 1578094)
10. PubMed 25788952 (PubMed 25788952)
11. PubMed 18831918 (PubMed 18831918)
12. PubMed 40362785 (PubMed 40362785)
13. PubMed 23688534 (PubMed 23688534)
14. PubMed 19140159 (PubMed 19140159)
15. PubMed 34826140 (PubMed 34826140)
16. PubMed 40431369 (PubMed 40431369)
17. PubMed 40880715 (PubMed 40880715)
18. PubMed 39236849 (PubMed 39236849)
19. PubMed 37648152 (PubMed 37648152)
20. PubMed 31655856 (PubMed 31655856)
21. PubMed 15813817 (PubMed 15813817)
22. PubMed 41915304 (PubMed 41915304)
23. PubMed 24153250 (PubMed 24153250)
24. PubMed 40396860 (PubMed 40396860)
25. PubMed 10859600 (PubMed 10859600)
26. PubMed 31470118 (PubMed 31470118)
27. PubMed 34209583 (PubMed 34209583)
28. PubMed 25889530 (PubMed 25889530)
29. PubMed 36069791 (PubMed 36069791)
30. PubMed 30961835 (PubMed 30961835)
31. PubMed 41728426 (PubMed 41728426)
32. PubMed 41305557 (PubMed 41305557)
33. PubMed 15050101 (PubMed 15050101)
34. PubMed 42346839 (PubMed 42346839)